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Out of the many forms of therapy for sudden deafness,
some require hospitalization and present significant risks.
Aim: This prospective study analyzes etiology and evolution
in cases of sudden deafness (SD) where outpatient oral
treatment was used. Study design: clinical with transversal
cohort. Material and Method: Forty cases of sudden
hearing loss were followed for at least one year. All were
submitted to initial clinical evaluation, auditory tests, routine
blood analysis, and magnetic resonance imaging. All received
initial treatment with pentoxifylline and prednisone. Results:
45% (n=18) presented normal auditory thresholds, 40%
(n=16) showed some improvement in hearing, 15% (n=6)
maintained initial hearing level. Nine cases (22.5%) presented
clinical conditions possibly implicated in hearing loss (viral
infection, immunomediated hearing loss, vascular disorders,
and so on); three (7.5%) had cerebellopontine tumors.
Evolution of hearing in these 12 cases with presumed
etiology presented no differences from hearing in the 28
cases without any known etiological factor. Clinical treatment
within the first seven days was the only statistically
significantly different condition in patients who improved
hearing. Conclusions: An objective search for etiological
bases should be conducted in any case of acute sensorineural
hearing loss. The presence of cerebellopontine tumors in
7.5% of cases of SD, among other treated causes, justifies a
thorough clinical investigation in these patients. Overall good
evolution of hearing was observed in 67.5% of cases of SD,
regardless of its etiology. Therapy within the first seven
days of SD was significantly related to better outcomes in
hearing.
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INTRODUCTION
Sudden Deafness (SD) is defined as hearing loss
greater than 30 dB in at least three subsequent frequencies
of sudden onset or within maximum 72 hours, and it
represents a common symptom to many different diseases
and not a nosological entity in itself. In many situations, the
etiology remains unknown and is a major challenge even
after complete otological assessment. These cases are
classified as idiopathic sudden deafness, and to those patients
there is no consensus about what is the best treatment option
or how the auditory recovery will be.
Different treatment approaches have been described,
but most studies are not controlled or double blind studies 1-
5. Moreover, spontaneous or placebo recovery rate is high
and similar to results in patients treated with different drugs.
Among the used drugs, corticoids seem to have universal
acceptance and they are the only ones with confirmed
efficacy 1. It is also common to use drugs that reduce blood
viscosity such as dextran or vasodilators such as carbogen.2,3
The use of antiviral therapies has increased, but the results
are still not satisfactory.4,5 In fact, the different forms of
treatment reflect the difficulties found in the treatment of a
patient who does not have defined etiological diagnosis.
Conversely, SD should be approached as an emergency,
given that early intervention is associated with the best
prognosis.3,6
To contribute to the understanding of cases of SD
and to promote better guidance in the cases of SD that
were seen in our service, we conducted a prospective study
for 2 years, analyzing the clinical and audiometric aspects,
basic lab tests and imaging exams of these patients. The
investigation of etiology of SD and the immediate observation
of auditory progression regardless of the etiological diagnosis
after the common initial treatment with prednisone and
pentoxifylline were the main objectives of this study.
MATERIAL AND METHOD
The study included 40 patients who were seen at
the Department of Otorhinolaryngology, Federal University
of Sao Paulo - Escola Paulista de Medicina, Sao Paulo, with
diagnosis of SD between the years 2000 and 2002. The
criteria for inclusion in the study were sensorineural hearing
loss greater than 30 dB in at least three subsequent
frequencies of sudden onset or maximum within 3 days. To
be included in the study we selected patients that had come
to the center within 20 days from the installation of SD. All
patients were submitted to a standard protocol for etiological
investigation, they were also treated similarly and followed
up for a minimum of 1 year.
Auditory assessment comprised pure tone and vocal
audiometry, impedanciometry with acoustic reflex and
speech recognition test. After the initial visit, the tests were
repeated weekly in the first month, monthly up to the 6th
month and then every six months up to discharge of the
patient. Initial lab tests included complete blood count, fast
glucose, total and fractioned cholesterol, triglyceride dosage
and erythrocyte sedimentation rate.
In some situations there was complementation of the
auditory assessment with distortion product otoacoustic
emissions and electrocochleography and lab tests with dosage
of proteins HSP 70 and 68 kD, FAN, dosage of complement
and viral serology (mumps, herpes simplex types I and II,
varicella zoster, cytomegalovirus, HIV and mononucleosis).
Imaging exams comprised magnetic resonance imaging
(MRI) of the encephalon, emphasis on temporal bone and
posterior fossa. All the exams were preferably performed
before or on the first days of treatment. We included in the
study only the patients that performed a minimum follow
up of one year and precisely complied with the clinical and
diagnosis protocol.
Initial treatment was performed with prednisone
1mg/kg/day, with tampering after 5 days and complete
withdrawal at the end of three weeks, in association with
pentoxifylline 400mg TID, which was maintained for 8
weeks. In patients who had etiological diagnosis of SD or
presence of comorbidities (diabetes, hypertension,
dyslipidemia) that required other drugs or approaches, they
were used associated with standard therapy. All patients were
treated in outpatient care.
The assessment of auditory recovery was performed
through rate of improvement, which measured the
perceptual auditory gain and used the contralateral side as a
reference.2
Rate of improvement (%) = Initial thresholds - Final
thresholds X 100
Initial thresholds - thresholds of
the contralateral ear
Auditory thresholds were calculated by using the
means of frequencies 250, 500, 1000, 2000, 4000 and 8000
Hz. The final threshold was calculated based on the last
audiometry, performed at least one year after the onset of
treatment, and in all cases, auditory thresholds of the
contralateral ear were below 30dB. Thus, it is evident that in
our sample, all losses were unilateral. The improvement rates
above 90% were defined as total recovery. Improvement
rates below 20% were considered therapeutic failure (no
response). Improvement percentage between 21 and 89%
was defined as partial recovery, between 51 and 89% the
recovery was considered good, and if it remained between
21 and 50%, it was considered fair.
The statistical analyses were performed using X²,
Fischer and Analysis of Variance (ANOVA) tests to check the
correlation between auditory recovery and age, gender, race,
affected side, type of curve, presence of associated diseases,
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MRI affections or temporal bone and encephalon
abnormalities, abnormal lab exams, concomitant symptoms,
severity of hearing loss and beginning of treatment. p value
should be below 0.05 to raise statistical significance.
To the statistical analysis, good results were the sum
of cases that had total recovery plus those that had partial
recovery and that presented improvement rate above 51%.
As dissatisfactory result, we considered the sum of those
who had therapeutic failure plus those with recovery rate
below 50%.
RESULTS
Out of 40 patients, 22 (55%) were male and 18 (45%)
were female and the mean age was 41 years, ranging from
13 to 76 years. The right ear was affected in 24 (60%) and
the left ear was affected in 16 (40%) patients. In 33 (82.5%)
patients the hearing loss was instantaneous and in 7 (17.5%)
it was progressive, but it was completely within 72 hours.
The presence of tinnitus was observed in 100% of the ca-
ses. Vertigo or imbalance was detected in 21 patients (52.5%)
and ear fullness in 15 cases (37.5%).
As to configuration of audiometric curve, flat losses
reaching all frequencies were the most frequent ones,
observed in 17 patients (42.5%); ascending curves were
observed in 10 cases (25%), descending in 9 (22.5%) patients,
and in 4 (10%) patients hearing loss affected preferably
medium frequencies. As to severity of hearing loss at the
diagnosis: 4 (10%) patients presented mild loss, 15 (37.5%)
had moderate loss, 5 (12.5%) had severe, and 16 (40%) had
profound loss.
The presence of associated diseases was found in 23
patients (57.5%) and systemic hypertension and diabetes
mellitus were found respectively in 9 (22%) and 5 (12%)
patients as the most frequent diseases. All these findings
were interpreted as comorbidities and not as cause of SD. A
small increase in erythrocyte sedimentation rate was the
most common lab test abnormality in the blood analysis of
these patients.
Temporal bone and encephalon MRI identified
affections to the central nervous system (CNS) or located in
the inner ear in 12 patients (30%). In the CNS, subcortical
lesions compatible with microangiopathy were found in 7
cases (17.5%). In 3 patients (7.5%) we observed
cerebellopontine angle tumors, and in one it was a
meningioma (2.5%) whereas in 2 (5%) they were vestibular
schwannomas. Inner ear hypersignal, identified at T1 after
contrast, suggesting inflammatory activity, was found in 2
(5%) patients. Microangiopathy was also considered as an
associated factor and not as the cause of SD.
In 12 patients (30%), a possible etiology of SD was
defined (Chart 1): in 3 cases (7.5%) it was an
immunomediated disease with diagnosis based on lab
findings, inflammatory activity observed in the inner ear at
MRI or improvement and stabilization of hearing depending
on the continuous administration of corticoids. Two (5%)
patients had vestibular schwannomas detected by MRI. Viral
infection was observed in 2 cases (5%), one with viral
encephalitis and the second with mumps, the first confirmed
through lumbar puncture and analysis of CSF and the second
with parotid region edema, confirming the evaluation of IgM
for mump virus and marked inflammatory activity in the
inner ear observed at MRI. There were 2 other cases with
vascular disorders, one with sickle cell anemia in an acute
episode concomitant to the SD, and the other had SD and
circulatory disorders that occurred during hemodialysis.
Meningioma of cerebellopontine angle identified by MRI
was seen in 1 patient (2.5%). Ménière disease with vertigo
and ear fullness occurred later during the follow up of the
patient and it was confirmed through affection at SP/AP ratio
in electrocochleography found in 1 patient (2.5%). One
patient (2.5%) had SD caused by barotrauma, observed
immediately after physical exercises at the gym.
During the follow up period, 18 patients (45%)
presented normal hearing, that is, recovery rate above 90%
and 9 (22.5%) presented partial improvement, with recovery
rates between 51% and 89%, amounting to a total of 27
(67.5%) patients with satisfactory progression. The total
Chart 1. Possible etiology of sudden deafness.
Nº Etiology Rate of improvement Diagnosis
01 Rupture of membrane 100 History
02 Schwannoma 100 MRI
03 Vascular 100 History / Lab tests
04 Immunomediated 100 Lab tests
05 Meningioma 100 MRI
06 Viral 100 History /Lab tests
07 Immunomediated 51 History / Lab tests
08 Méniere 45 History/Lab tests
09 Vascular 38.5 History
10 Immunomediated 36.6 Progression / Lab tests
11 Schwannoma 8.6 MRI
12 Viral 0 History/Lab tests
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number of cases with dissatisfactory progression was 13
(32.5%) patients, being 6 (15%) without responses, whose
rates of auditory recovery were up to 20%, and 7 (17.5%)
with poor response, with recovery rates between 21 and
50% (Graph 1).
It is interesting to observe that auditory
recovery in statistical terms between the patients with defined
etiological diagnosis and idiopathic cases of SD was similar
(Fischer test, p=0.195, Graph 2). Other analyzed clinical
aspects with the possible relation in auditory recovery were
age, gender, race, involved side, audiometric configuration,
initial level of hearing loss, concomitant symptoms, associated
diseases, MRI observed affections and lab tests that did not
statistically differ in auditory recovery. The exception was
observed in time of beginning of treatment, because the
patients that started treatment with prednisone and
pentoxifylline in the first 7 days after onset of SD had better
auditory recovery when compared to those that started
treatment later (p<0.05) (Graph 3).
DISCUSSION
When we discuss SD, the terminology should be well
defined, given that there is no uniformity about this topic in
the literature. In some situations, SD may refer only to cases
in which there is sudden sensorineural loss of idiopathic origin,
but, in most cases, we are referring to all forms of
sensorineural loss of sudden manifestation, regardless of the
etiological diagnosis.
Another aspect to be considered is the method
employed to assess auditory recovery in SD. Different criteria
are used, some assess absolute gain in decibel (dB),
calculating the difference between final and initial
audiometry, without taking into account the severity of
hearing loss. The failure in this analysis is that the gain of 20
dB in a patient with a mild or moderate loss has completely
different functional meaning when compared to profound
loss. Another form normally used to analyze the results is
the investigation of the so-called relative auditory gain, which
is calculated by the percentage of improvement between
final and initial audiometry of the patient. In this situation,
the analysis of auditory recovery is more reliable, given that
the percentage value has the same weight regardless of the
hearing loss severity. In our study, we used the rate of
auditory improvement which, in addition to analyzing the
percentage of recovery of the affected ear, considers the
contralateral hearing as a reference. According to these
criteria, the patient is classified in an increasing scale of
improvement and not in static groups, in which the
intragroup variation is very high. It represents the best
parameter to assess auditory recovery and predicts efficacy
of treatment.7
The percentage of spontaneous improvement ran-
ges, according to the literature, from 45 to 65%7,8 and available
Graph 1. Rate of auditory improvement after 1 year.
Graph 2. Etiological diagnosis and auditory recovery.
Graph 3. Time from onset of treatment and auditory improvement.
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treatment options present similar results. In part, this
percentage variation occurs owing to more or less flexibility
in the use of improvement criteria. In studies about gain of
10dB in relation to initial audiometry we consider it an
improvement, and the rates tend to come close to 80%.4 In
our study, we only considered complete auditory
improvement when the recovery rates were over 90% and
had significant improvement when they were over 50%,
much more rigorous values than those described in the
literature 3. Even so, by adding up the two groups, the
improvement rate observed was 67.5%, which is similar to
the rate described by other authors with other therapies.3,8-
10
In our study, we used a previously defined protocol
in all patients with SD that came to the Emergency room,
and diagnosis of etiology was found in 30% of the cases.
Other studies reported identification of etiology in only 10
to 15% of the cases 6,9. These differences may be justified
by the use of different clinical protocols that may have
different sensitivity levels.
In our study, we found cerebellopontine angle tumors
in 7.5% of the cases, findings that were higher than what
was reported in the literature 5. It was even more interesting
to perceive that vestibular schwannoma presented total
recovery of hearing after the advocated initial treatment.
This fact had been described before 5, and auditory recovery
could interfere in the choice of surgical access, influencing
the auditory prognosis of these patients.
SD treatment is another topic that generates much
discussion. A wide range of therapeutic modalities may be
found in the literature, some are complex and uncommon,
but they have the same efficacy. Most treatment approaches
are based on a possible circulation disorder or inflammatory
reaction that affects the inner ear 8. However, histological
analyses of the cochlea of patients who had SD presented
affections compatible with viral lesions.11,12 Despite these
histological evidences and experimental studies
demonstrating the efficacy of antiviral in the treatment of
SD 13, the beneficial effects of antiviral in humans have not
been confirmed yet.4,5 Wide spectrum therapies that would
theoretically treat both vascular and inflammatory disorders
are widely used in clinical practice; in part, because there
are no treatments with recognized efficacy and also owing
to the anxiety that involves the physician-patient relationship
in these cases. However, there is no evidence that this type
of approach has produced better results than monotherapy.9
There are few controlled studies in the literature and
only corticoids seem to have actually shown any benefit in
the treatment of SD.1,9,14 As to vasodilators, even though
they are widely used, there is still scarcity of studies with
more rigid scientific controls that confirm their positive effects
in the treatment of SD.9 In fact, the attempts to confirm the
increase in cochlear blood flow with the use of these drugs
have been inconsistent.10 Pentoxifylline, a medication with
hemorheological effects, reduces blood viscosity improving
the blood flow in the labyrinth and, as previously described,
it presents beneficial effects in patients with SS.15 The option
to use prednisone associated with pentoxifylline in our study
was a result of the fact that both can be used as outpatient
drugs, preventing the inconvenience of hospitalization and
minimizing the potential risks of the use of intravenous
vasodilators or corticoids.
The purpose of our study was not compare different
therapies. Our focus was on the etiological identification of
SD and the follow up of immediate progression of these
patients after common therapy with pentoxifylline and
prednisone.
As to demographical characteristics, our results were
similar to most of those described in the literature, with mean
age of patients in the 5th decade of life and with no
predominance of side or gender.3,4,6
Differently from other authors, we did not find any
correlation between type of audiometric curve or severity
of hearing loss in auditory recovery4. There were patients
with mild losses that did not recover hearing and others
with profound loss who fully recovered it. There was
predominance of audiometric curves of flat configuration,
which presented similar losses in all frequencies. Ascending
curves or those with predominance of medium frequencies
did not show better prognosis in our sample than what was
described in the literature.6
The presence of associated symptoms, such as tinnitus
and vertigo, was related with worse prognosis by many
authors 3,4,16. In our sample, vestibular symptoms of vertigo
and imbalance were present in 52.5% of the patients, but
the presence of tinnitus was greater than what had been
reported by other authors 3,4, affecting at the beginning of
the presentation 100% of the patients. However, none of
the symptoms presented any correlation with degree of
auditory recovery in the study.
The presence of concomitant diseases occurred in
60% of the cases and the presence has also not affected the
auditory prognosis of the study. Given that mean age of the
patients was high, the presence of concomitant diseases
was correlated with their own characteristics, more than with
SD. The frequent finding of microangiopathy in CNS observed
at MRI helped us confirm this fact given that diabetes mellitus
and hypertension were the most prevalent diseases in the
groups of patients. This finding was not considered an
etiological factor of SD.
The only statistically significant prognostic factor was
early onset of therapy. The patients that were seen within 1
week from onset of condition presented better hearing
recovery rates, a similar finding to that of other authors 3,6.
The initial analysis of this piece of information could suggest
that treatment is more effective than natural progression of
the disease. However, given that SD may quickly recover,
some patients with this type of progression do not come to
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the medical center and, thus, the finding of better progression
in the case of early introduction of the drug could represent
one more effect of natural progression of SD rather than the
treatment per se. In the group that started treatment more
than 1 week after onset we can include most of the patients
that did not present spontaneous improvement, explaining
the difference in auditory recovery between the two groups.
Only a double blind and placebo-controlled study could
separate the natural progression from good results with the
adopted treatment. However, the studies with this
methodological design are difficult to perform for obvious
ethical issues.
When we compare auditory progression between
patients with idiopathic SD and those in which etiological
diagnosis was made, we did not observe statistically significant
differences between them, despite the more directed
treatment to patients with specific etiology. This observation
shows that despite the diagnostic advances obtained with
the routine performance of new laboratory exams or imaging
exams in patients with SD, which have reduced the number
of idiopathic cases, the therapeutic success of the attempt
to improve auditory function of these patients is still limited,
despite the possibility of performing a more specific
treatment, especially in cases associated with viral diseases.
CONCLUSION
The objective investigation of etiology should be
performed in any case of SD. The presence of
cerebellopontine tumors in 7.5% of the cases of SD, among
other causes, justifies complete investigation in these patients.
Good progression, with improvement of 67.5% of the cases
of SD, was observed regardless of the etiological diagnosis.
The beginning of therapy within the first week from onset
was the only factor related with better auditory results in
these patients.
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